Close

content

Immune Pharmaceuticals Enters a Research Partnership to Develop Mono and Bispecific Antibodies  

Immune Pharmaceuticals Inc , a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of immuno-inflammatory diseases and cancers. Announced that...

WuXi AppTec Acquires Biology Focused R&D Service Leader HD Biosciences

WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform announced that it has acquired HD Biosciences (HDB), a...

Gilead Sciences, Inc. Announces EMA Validation of Marketing Authorization Application for Investigational Chronic

Gilead Sciences, Inc announced that the company’s Marketing Authorization Application for the investigational, once-daily, single tablet regimen of sofosbuvir 400 mg. ...

Takeda Recognized as one of the Global 100 Most Sustainable Corporations for second consecutive year

Takeda Pharmaceutical Company Limited ,is proud to be named by Corporate Knights to the 2017 Global 100 Most Sustainable Corporations in the World Index....

PharmAthene and Altimmune Announce Merger to Create Immunotherapeutics Company Targeting Infectious Diseases

PharmAthene, Inc. and Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious diseases, announced the signing of a definitive agreement for the merger of PharmAthene...

Evotec enters into an integrated drug discovery collaboration with Asahi Kasei Pharma

Evotec AG announced it has entered into an integrated drug discovery collaboration on an ion channel target with Asahi Kasei Pharma Corporation, a wholly...

New UK primary care clinical trials company Interface Clinical Research to offer a more effective model

New clinical trials company, Interface Clinical Research, outlined a new model for running primary care clinical trials at their launch yesterday at the Royal...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read